Arab Finance: The Financial Regulatory Authority (FRA) has approved publishing the disclosure form proposed by the Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents’ (Rameda) board to decrease its issued and paid up capital via writing off 9.47 million treasury shares, as per a filing.

Hence, the capital shall be trimmed by EGP 2.368 million to EGP 375.866 million.

Rameda is an Egypt-based pharmaceutical company that manufactures both human and veterinary pharmaceuticals.

It operates three fully independent factories at its plant, including 20 production lines capable of producing a wide range of general medicinal forms, namely eye drops, solid dosage forms, syrups, blow-fill-seal, and lyophilized vials, among others.

Oliv receives Egypt’s 1st digital factoring license from FRA Updated 12/16/2024 8:28:00 AM

FRA nods to Emaar Misr’s issued capital increase Updated 12/10/2024 1:45:00 PM

Egypt delays launch of financial derivatives market until Q2 2025 Updated 12/10/2024 6:38:00 AM

Beltone Capital, CRIF sign JV deal to expand rating solutions in MENA Updated 12/9/2024 8:36:00 AM

Egypt’s non-banking finance hit EGP 646.6B in 9 months: FRA Updated 12/3/2024 6:45:00 AM